CriticalSorb™: Enabling systemic delivery of macromolecules via the nasal route

Drug Delivery and Translational Research

Volumn 3, Issue 1, 2013, Pages 26-32

  Lewis, Andrew L ^a   Jordan, Faron ^a   Illum, Lisbeth ^b  

^a Critical Pharmaceuticals Limited   (United Kingdom)

^b IDentity   (United Kingdom)

Author keywords

Absorption enhancer; CriticalSorb ; Nasal; Permeation enhancement

Indexed keywords

HUMAN GROWTH HORMONE; INSULIN; SOLUTOL HS 15;

ABSORPTION; AREA UNDER THE CURVE; ARTICLE; DRUG DELIVERY SYSTEM; IN VIVO STUDY; INTRANASAL DRUG ADMINISTRATION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIMATE; PRIORITY JOURNAL; RABBIT; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84875546876     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-012-0089-8     Document Type: Article

References (33)

1. Evers P. The future of the biologicals market: market overview, innovations and company profiles. London: Business Insights Limited; 2010.
2. Pavlou F. 50 % of MS patients avoid treatment over injectable delivery fears. Pharmatech. com © 2009 Advanstar Communications, Inc.
3. Frost & Sullivan. European human growth hormone market. Frost & Sullivan Research Service. London. 2008.
4. Cutfield WS, Derraik JGB, Gunn AJ, Reid K, Delany T, Robinson E, et al. Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS One; 6(1).
5. Flood EM, Ryan KJ, Rousculp MD, Beusterien KM, Block SL, Hall MC, et al. A survey of children's preferences for influenza vaccine attributes. Vaccine. 2011; 29(26): 4334-40.
6. Liu Y, Johnson MR, Matida EA, Kherani S, Marsan J. Creation of a standardized geometry of the human nasal cavity. J Appl Physiol. 2009; 106(3): 784-95.
7. Illum L, Watts P, Fisher AN, Hinchcliffe M, Norbury H, Jabbal-Gill I, et al. Intranasal delivery of morphine. J Pharmacol Exp Ther. 2002; 301(1): 391-400.
8. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release. 2003; 87(1-3): 187-98.
9. Illum L. Nasal drug delivery-recent developments and future prospects. J Control Release. 2012; 161(2): 254-63.
10. Brayden DJ, BVA, Lewis AL, Illum L. CriticalSorb™ promotes permeation of flux markers across isolated rat intestinal mucosae and Caco-2 monolayers. Pharm Res. 2012. doi: 10. 1007/s11095-012-0785-6.
11. L. Illum FJ, Lewis AL. Preclinical pharmacokinetics and pharmacodynamics of intranasal CriticalSorb insulin. 2012. (in press).
12. Mayor SH, Illum L. Investigation of the effect of anaesthesia on nasal absorption of insulin in rats. Int J Pharm. 1997; 149(1): 123-9.
13. L. Illum FJ, Lewis AL. CriticalSorb: a novel efficient nasal delivery system for human growth hormone. J Control Release. 2012. (in press).
14. L. Illum FJ, Lewis AL, editors. Nasal delivery of peptides and proteins-are we there yet? 37th Annual Meeting and Exposition of the Controlled Release Society. Portland, Oregon, USA; 2010.
15. Lewis FMJ AL, Jordan FM, Illum L. Dry powder criticalsorb formulations promote absorption of macromolecules across the nasal mucosa of rabbits. J Pharm Pharmacol. 2010; 62(10): 1227.
16. Leary AC, Stote RM, Cussen K, O'Brien J, Leary WP, Buckley B. Pharmacokinetics and pharmacodynamics of intranasal insulin administered to patients with type 1 diabetes: a preliminary study. Diabetes Technol Ther. 2006; 8(1): 81-8.
17. Leary AC, Stote RM, Breedt HJ, O'Brien J, Buckley B. Pharmacokinetics and pharmacodynamics of intranasal insulin administered to healthy subjects in escalating doses. Diabetes Technol Ther. 2005; 7(1): 124-30.
18. Stote R, Marbury T, Shi L, Miller M, Strange P. Comparison pharmacokinetics of two concentrations (0. 7 % and 1. 0 %) of Nasulin, an ultra-rapid-acting intranasal insulin formulation. J Diabetes Sci Technol. 2010; 4(3): 603-9.
19. Stote R, Miller M, Marbury T, Shi L, Strange P. Enhanced absorption of Nasulin, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects. J Diabetes Sci Technol. 2011; 5(1): 113-9.
20. Leary AC, Dowling M, Cussen K, O'Brien J, Stote RM. Pharmacokinetics and pharmacodynamics of intranasal insulin spray (Nasulin) administered to healthy male volunteers: influence of the nasal cycle. J Diabetes Sci Technol. 2008; 2(6): 1054-60.
21. Schwartz S, Ryan T, Carmichael C, Stote R. Interim results of a randomized, single-dose, 4-way crossover, pharmacokinetic study of intranasal insulin spray (Nasulin (TM)), injectable regular insulin (Humulin R), injectable fast-acting insulin (Humalog), and saline nasal spray in patients with type I diabetes. Diabetes. 2007; 56: A10-A.
22. Stote R, Schwartz S, Shi L, Strange P. Hypoglycemia advantage of Nasulin (TM) (an investigational intranasal insulin spray) in type 1 diabetic subjects; PK comparison over time. Diabetes. 2010; 59: A579-A.
23. Arnold JJ, Ahsan F, Meezan E, Pillion DJ. Correlation of tetradecylmaltoside induced increases in nasal peptide drug delivery with morphological changes in nasal epithelial cells. J Pharm Sci. 2004; 93(9): 2205-13.
24. Arnold JJ, Fyrberg MD, Meezan E, Pillion DJ. Reestablishment of the nasal permeability barrier to several peptides following exposure to the absorption enhancer tetradecyl-beta-D-maltoside. J Pharm Sci. 2010; 99(4): 1912-20.
25. Charlton S, Jones NS, Davis SS, Illum L. Distribution and clearance of bioadhesive formulations from the olfactory region in man: effect of polymer type and nasal delivery device. Eur J Pharm Sci. 2007; 30(3-4): 295-302.
26. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res. 1998; 15(9): 1326-31.
27. Illum L, Watts P, Fisher AN, Gill IJ, Davis SS. Novel chitosan- based delivery systems for the nasal administration of a LHRH- analogue. S. T. P. Pharma Sci. 2000; 10(1): 89-94.
28. Cheng YH, Dyer AM, Jabbal-Gill I, Hinchcliffe M, Nankervis R, Smith A, et al. Intranasal delivery of recombinant human growth hormone (somatropin) in sheep using chitosan-based powder formulations. Eur J Pharm Sci. 2005; 26(1): 9-15.
29. Bacon A, Makin J, Sizer PJ, Jabbal-Gill I, Hinchcliffe M, Illum L, et al. Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens. Infect Immun. 2000; 68(10): 5764-70.
30. Read RC, Naylor SC, Potter CW, Bond J, Jabbal-Gill I, Fisher A, et al. Effective nasal influenza vaccine delivery using chitosan. Vaccine. 2005; 23(35): 4367-74.
31. McNeela EA, O'Connor D, Jabbal-Gill I, Illum L, Davis SS, Pizza M, et al. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine. 2000; 19(9-10): 1188-98.
32. Mills KHG, Cosgrove C, McNeela EA, Sexton A, Giemza R, Jabbal-Gill I, et al. Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a. Infect Immun. 2003; 71(2): 726-32.
33. Maggio ET. Intravail: highly effective intranasal delivery of peptide and protein drugs. Expert Opin Drug Deliv. 2006; 3(4): 529-39.